Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-08 9:54 pm Unchanged | 2021-02-05 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 4,267,564 8.800% | 0 (Unchanged) | Filing History |
| 2021-02-08 5:00 pm Unchanged | 2021-02-05 | 13D | Arcutis Biotherapeutics, Inc. ARQT | Bain Capital Life Sciences Fund L.P. | 3,609,796 7.400% | 0 (Unchanged) | Filing History |
| 2021-02-08 10:15 am Purchase | 2021-02-05 | 13G | Arcutis Biotherapeutics, Inc. ARQT | FMR LLC | 6,545,164 14.999% | 2,486,155 (+61.25%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Arcutis Biotherapeutics, Inc. ARQT | BlackRock Inc. BLK | 2,895,054 6.600% | 2,895,054 (New Position) | Filing History |
| 2020-10-07 5:08 pm Purchase | 2020-10-02 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 4,267,564 9.900% | 200,000 (+4.92%) | Filing History |
| 2020-10-06 2:42 pm Unchanged | 2020-10-06 | 13D | Arcutis Biotherapeutics, Inc. ARQT | Frazier Life Sciences VIII L.P. | 10,542,790 24.100% | 0 (Unchanged) | Filing History |